Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTRobert Izquierdo, The Motley FoolSun, July 5, 2026 at 11:38 PM GMT+2 4 min readHedge fund JW Asset Management, LLC reported the indirect sale of 90,533 shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) across multiple open-market transactions from May 26, 2026 through May 28, 2026, totaling approximately $6.64 million in proceeds according to the SEC Form 4 filing.Transaction summaryMetricValueShares sold (indirect)90,533Transaction value$6.6 millionPost-transaction shares (indirect)2,890,582Transaction value based on SEC Form 4 weighted average reported price ($73.31).Key questionsWhat is the magnitude of this transaction relative to prior trades by JW Asset Management?The 90,533 shares sold exceed the average historical sale size of ~25,263 shares.How does the sale affect the insider's continuing exposure to Establishment Labs?JW Asset Management disclosed no direct holdings in this filing, and continues to hold 2,890,582 shares indirectly after the transaction.Were all shares sold through open-market transactions, and which entities were involved?Yes, all 90,533 shares were sold indirectly via open-market transactions by JW Partners, LP and JW Opportunities Fund, LLC, with no direct or derivative activity reported.Is the current sale consistent with the historical disposition pattern?The cadence and scale of this trade align with a disciplined reduction of the available position, consistent with prior sales and dictated by remaining share capacity.Company overviewMetricValuePrice (as of market close 2026-05-28)$72.98Market capitalization$2.08 billionRevenue (TTM)$229.58 millionNet income (TTM)-$43.74 million* 1-year performance is calculated using May 28th, 2026 as the reference date.Company snapshotEstablishment Labs offers silicone gel-filled breast implants (Motiva Implants, Motiva Ergonomix, Motiva Ergonomix2), tissue expanders, and autologous tissue harvesting devices.It generates revenue primarily through the manufacture and sale of proprietary medical devices for aesthetic and reconstructive plastic surgery, distributed via exclusive distributors and direct sales channels.The company targets plastic surgeons and healthcare providers across Europe, Latin America, Asia-Pacific, and other international markets.Establishment Labs Holdings Inc. is a global medical technology company specializing in advanced breast implant systems and related medical devices. The company leverages proprietary technologies and a diversified product portfolio to address both aesthetic and reconstructive needs in plastic surgery. Its international distribution network and focus on innovation provide a competitive advantage in the medical devices sector.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info